Servier, an independent international pharmaceutical group, has published its financial results for the 2022-2023 financial year and highlighted the milestones that marked the year, particularly in R&D.

Read the details of the Financial report

Key Highlights

  • Consolidated sales revenue of €5.327 billion, up 9.2% (+12% at CERi) compared to 2021-2022, driven by strong growth in international sales
  • Performance fueled by growth in sales volumes of both brand-name medicines (€4.041 billion, +9.4%) and generics (€1.286 billion, +8.8%)
  • Strong performance in oncology sales, which exceeded the symbolic €1 billion mark
  • Major breakthroughs in oncology, addressing high unmet medical needs
  • A promising and robust R&D pipeline, bringing hope to patients
Olivier Laureau, Servier's CEO: In 2022-2023, Servier performed well on the strength of an innovative portfolio in oncology and a strong incremental innovation strategy in cardiometabolism and venous diseases.

07/02/2024